The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of these two cytokines on T cells, natural killer cells, and antigen-presenting cells.

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness of vedolizumab (Entyvio) versus ustekinumab (Stelara) and of each ...

Patients with moderate to severe psoriasis treated with ustekinumab and guselkumab showed a trend towards a lower risk for herpes zoster (HZ) and postherpetic neuralgia (PHN) than those receiving ...

ORLANDO -- First-dose reactions to IV ustekinumab (Stelara) may be related to IgE recognition of a carbohydrate allergen in patients, who may be able to tolerate subcutaneous ustekinumab instead ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence ...

--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar ...